In the European Union, Enhertu’s approvals remain specific to certain cancer types, such as breast cancer (HER2-positive and HER2-low), gastric or gastroesophageal junction adenocarcinoma (HER2 -positive), and NSCLC with activating HER2. This evidence concerns the gene ERBB2 and breast cancer.